Annual CFF
$128.40 M
+$129.44 M+12434.49%
31 March 2024
Summary:
VistaGen Therapeutics annual cash flow from financing activities is currently $128.40 million, with the most recent change of +$129.44 million (+12434.49%) on 31 March 2024. During the last 3 years, it has risen by +$14.30 million (+12.53%). VTGN annual CFF is now at all-time high.VTGN Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFF
$0.00
-$88.00 K-100.00%
30 September 2024
Summary:
VistaGen Therapeutics quarterly cash flow from financing activities is currently $0.00, with the most recent change of -$88.00 thousand (-100.00%) on 30 September 2024. Over the past year, it has dropped by -$34.18 million (-100.00%). VTGN quarterly CFF is now -100.00% below its all-time high of $94.07 million, reached on 31 December 2020.VTGN Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFF
$93.44 M
-$34.18 M-26.78%
30 September 2024
Summary:
VistaGen Therapeutics TTM cash flow from financing activities is currently $93.44 million, with the most recent change of -$34.18 million (-26.78%) on 30 September 2024. Over the past year, it has increased by +$59.09 million (+172.02%). VTGN TTM CFF is now -27.23% below its all-time high of $128.40 million, reached on 31 March 2024.VTGN TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
VTGN Cash From Financing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +10000.0% | -100.0% | +172.0% |
| 3 y3 years | +12.5% | -100.0% | -12.3% |
| 5 y5 years | +637.0% | +100.0% | +641.1% |
VTGN Cash From Financing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | >+9999.0% | -100.0% | +100.0% | -27.2% | +9075.9% |
| 5 y | 5 years | at high | >+9999.0% | -100.0% | +100.0% | -27.2% | +9075.9% |
| alltime | all time | at high | >+9999.0% | -100.0% | +100.0% | -27.2% | +9075.9% |
VistaGen Therapeutics Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $0.00(-100.0%) | $93.44 M(-26.8%) |
| June 2024 | - | $88.00 K(-152.4%) | $127.61 M(-0.6%) |
| Mar 2024 | $128.40 M(<-9900.0%) | -$167.80 K(-100.2%) | $128.40 M(+0.2%) |
| Dec 2023 | - | $93.52 M(+173.6%) | $128.17 M(+273.1%) |
| Sept 2023 | - | $34.18 M(+3805.8%) | $34.35 M(<-9900.0%) |
| June 2023 | - | $875.00 K(-320.2%) | -$160.50 K(-84.6%) |
| Mar 2023 | -$1.04 M(-109.9%) | -$397.40 K(+30.7%) | -$1.04 M(+67.9%) |
| Dec 2022 | - | -$304.10 K(-9.0%) | -$619.90 K(-134.4%) |
| Sept 2022 | - | -$334.00 K(+5972.7%) | $1.80 M(-81.0%) |
| June 2022 | - | -$5500.00(-123.2%) | $9.49 M(-9.5%) |
| Mar 2022 | $10.48 M(-90.8%) | $23.70 K(-98.9%) | $10.48 M(-27.9%) |
| Dec 2021 | - | $2.12 M(-71.2%) | $14.54 M(-86.3%) |
| Sept 2021 | - | $7.35 M(+641.4%) | $106.50 M(-5.0%) |
| June 2021 | - | $991.40 K(-75.7%) | $112.10 M(-1.8%) |
| Mar 2021 | $114.10 M(+2744.2%) | $4.08 M(-95.7%) | $114.10 M(+1.1%) |
| Dec 2020 | - | $94.07 M(+626.5%) | $112.89 M(+462.0%) |
| Sept 2020 | - | $12.95 M(+332.0%) | $20.09 M(+184.9%) |
| June 2020 | - | $3.00 M(+4.4%) | $7.05 M(+75.8%) |
| Mar 2020 | $4.01 M(-77.0%) | $2.87 M(+126.0%) | $4.01 M(-65.2%) |
| Dec 2019 | - | $1.27 M(-1545.4%) | $11.52 M(-8.6%) |
| Sept 2019 | - | -$87.90 K(+110.3%) | $12.61 M(-27.4%) |
| June 2019 | - | -$41.80 K(-100.4%) | $17.36 M(-0.4%) |
| Mar 2019 | $17.42 M(+5.5%) | $10.38 M(+339.5%) | $17.42 M(+149.0%) |
| Dec 2018 | - | $2.36 M(-49.4%) | $7.00 M(-61.9%) |
| Sept 2018 | - | $4.66 M(>+9900.0%) | $18.35 M(+16.9%) |
| June 2018 | - | $23.60 K(-147.3%) | $15.70 M(-4.9%) |
| Mar 2018 | $16.52 M(+65.3%) | -$49.90 K(-100.4%) | $16.52 M(-0.7%) |
| Dec 2017 | - | $13.71 M(+581.0%) | $16.64 M(+430.0%) |
| Sept 2017 | - | $2.01 M(+139.4%) | $3.14 M(+187.8%) |
| June 2017 | - | $841.00 K(+1063.2%) | $1.09 M(-89.1%) |
| Mar 2017 | $9.99 M(+92.4%) | $72.30 K(-65.9%) | $9.99 M(-5.0%) |
| Dec 2016 | - | $212.30 K(-706.6%) | $10.52 M(-11.9%) |
| Sept 2016 | - | -$35.00 K(-100.4%) | $11.95 M(-15.0%) |
| June 2016 | - | $9.74 M(+1520.3%) | $14.06 M(+170.8%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2016 | $5.19 M(+82.9%) | $601.40 K(-63.3%) | $5.19 M(-6.3%) |
| Dec 2015 | - | $1.64 M(-21.2%) | $5.54 M(+30.2%) |
| Sept 2015 | - | $2.08 M(+137.8%) | $4.26 M(+85.1%) |
| June 2015 | - | $874.30 K(-8.1%) | $2.30 M(-19.0%) |
| Mar 2015 | $2.84 M(+89.6%) | $951.30 K(+168.6%) | $2.84 M(+21.6%) |
| Dec 2014 | - | $354.20 K(+193.0%) | $2.33 M(+0.9%) |
| Sept 2014 | - | $120.90 K(-91.4%) | $2.31 M(-14.9%) |
| June 2014 | - | $1.41 M(+216.4%) | $2.72 M(+81.4%) |
| Mar 2014 | $1.50 M(-64.0%) | $446.40 K(+34.2%) | $1.50 M(-43.3%) |
| Dec 2013 | - | $332.60 K(-36.7%) | $2.64 M(-22.6%) |
| Sept 2013 | - | $525.40 K(+172.1%) | $3.41 M(-16.8%) |
| June 2013 | - | $193.10 K(-87.8%) | $4.10 M(-1.3%) |
| Mar 2013 | $4.16 M(+17.4%) | $1.59 M(+43.8%) | $4.16 M(+29.1%) |
| Dec 2012 | - | $1.10 M(-9.2%) | $3.22 M(-1.0%) |
| Sept 2012 | - | $1.22 M(+392.5%) | $3.25 M(+71.3%) |
| June 2012 | - | $246.90 K(-62.1%) | $1.90 M(-46.4%) |
| Mar 2012 | $3.54 M(>+9900.0%) | $652.20 K(-42.6%) | $3.54 M(+22.3%) |
| Dec 2011 | - | $1.14 M(-926.2%) | $2.89 M(+64.5%) |
| Sept 2011 | - | -$137.50 K(-107.3%) | $1.76 M(-7.3%) |
| June 2011 | - | $1.89 M(>+9900.0%) | $1.90 M(>+9900.0%) |
| Mar 2011 | - | $6000.00(+275.0%) | $11.10 K(+37.0%) |
| Dec 2010 | $8100.00(+440.0%) | $1600.00(+220.0%) | $8100.00(+24.6%) |
| Sept 2010 | - | $500.00(-83.3%) | $6500.00(-13.3%) |
| June 2010 | - | $3000.00(0.0%) | $7500.00(+66.7%) |
| Mar 2010 | - | $3000.00(>+9900.0%) | $4500.00(+200.0%) |
| Dec 2009 | $1500.00(-96.0%) | $0.00(-100.0%) | $1500.00(-96.1%) |
| Sept 2009 | - | $1500.00(>+9900.0%) | $38.40 K(+4.1%) |
| June 2009 | - | $0.00(0.0%) | $36.90 K(0.0%) |
| Mar 2009 | - | $0.00(-100.0%) | $36.90 K(-1.3%) |
| Dec 2008 | $37.40 K | $36.90 K(>+9900.0%) | $37.40 K(+7380.0%) |
| Sept 2008 | - | $0.00(0.0%) | $500.00(0.0%) |
| June 2008 | - | $0.00(-100.0%) | $500.00(0.0%) |
| Mar 2008 | - | $500.00(>+9900.0%) | $500.00(>+9900.0%) |
| Mar 2007 | - | $0.00 | $0.00 |
FAQ
- What is VistaGen Therapeutics annual cash flow from financing activities?
- What is the all time high annual CFF for VistaGen Therapeutics?
- What is VistaGen Therapeutics annual CFF year-on-year change?
- What is VistaGen Therapeutics quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for VistaGen Therapeutics?
- What is VistaGen Therapeutics quarterly CFF year-on-year change?
- What is VistaGen Therapeutics TTM cash flow from financing activities?
- What is the all time high TTM CFF for VistaGen Therapeutics?
- What is VistaGen Therapeutics TTM CFF year-on-year change?
What is VistaGen Therapeutics annual cash flow from financing activities?
The current annual CFF of VTGN is $128.40 M
What is the all time high annual CFF for VistaGen Therapeutics?
VistaGen Therapeutics all-time high annual cash flow from financing activities is $128.40 M
What is VistaGen Therapeutics annual CFF year-on-year change?
Over the past year, VTGN annual cash flow from financing activities has changed by +$129.44 M (+12434.49%)
What is VistaGen Therapeutics quarterly cash flow from financing activities?
The current quarterly CFF of VTGN is $0.00
What is the all time high quarterly CFF for VistaGen Therapeutics?
VistaGen Therapeutics all-time high quarterly cash flow from financing activities is $94.07 M
What is VistaGen Therapeutics quarterly CFF year-on-year change?
Over the past year, VTGN quarterly cash flow from financing activities has changed by -$34.18 M (-100.00%)
What is VistaGen Therapeutics TTM cash flow from financing activities?
The current TTM CFF of VTGN is $93.44 M
What is the all time high TTM CFF for VistaGen Therapeutics?
VistaGen Therapeutics all-time high TTM cash flow from financing activities is $128.40 M
What is VistaGen Therapeutics TTM CFF year-on-year change?
Over the past year, VTGN TTM cash flow from financing activities has changed by +$59.09 M (+172.02%)